{"id":78585,"date":"2026-03-17T12:05:42","date_gmt":"2026-03-17T12:05:42","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/"},"modified":"2026-03-17T12:05:42","modified_gmt":"2026-03-17T12:05:42","slug":"acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/","title":{"rendered":"Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery&#x2122;, Biomarker Research, and Novel Antibodies at Advances in Alzheimer&#8217;s Treatment at International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2026"},"content":{"rendered":"<div>\n<p align=\"justify\">NEWTON, Mass., March  17, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=y69emsALS-aEtuDeXe3Ui846Q_PgHDxVMcYiQ_NsrGk4hEj-8__OWLMbsfjqhukQnUrfOPmgaD_DAnFylpc2PFvU-DIVbcWTik5rwg_JRRk=\" rel=\"nofollow\" target=\"_blank\" title=\"Acumen Pharmaceuticals, Inc.\">Acumen Pharmaceuticals, Inc.<\/a> (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease (AD), today announced new research findings at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders (AD\/PD), taking place March 17-21, in Copenhagen and online. Shared in one oral and two poster presentations, the data showcase efforts to advance AD treatment through three key areas which include: developing enhanced brain delivery (EBD&#x2122;) methods for sabirnetug by developing bispecific antibodies that additionally target Transferrin receptors to improve drug penetration across the blood-brain barrier; evaluating novel biomarker approaches using NULISAseq&#x2122; technology to better monitor treatment responses in the central nervous system; and creating highly selective antibodies that specifically target toxic A\u03b2Os while avoiding non-toxic monomeric forms of the protein.<\/p>\n<p align=\"justify\">\u201cThese presentations collectively demonstrate how we\u2019re addressing the key challenges that have limited success in Alzheimer\u2019s drug development \u2013 delivery, measurement, timing, and selectivity,\u201d said Jim Doherty, President and Chief Development Officer of Acumen. \u201cOur enhanced brain delivery work with JCR Pharmaceuticals tackles the fundamental problem of increasing bioavailability of therapeutics across the blood-brain barrier, while our biomarker research provides better tools for measuring treatment effects \u2013 expanding our understanding of these effects and early disease mechanisms. Lastly, our novel antibody development is purposely driving toward an increased selectivity for oligomers to ensure we&#8217;re targeting the right pathological species. This integrated approach reflects our belief that successful Alzheimer\u2019s therapeutics require innovation across multiple aspects.\u201d<\/p>\n<p align=\"justify\"><strong>Enhanced Brain Delivery&#x2122; of Sabirnetug After Fusion with an Anti-Transferrin Receptor Antibody Fragment in a Mouse Model of Alzheimer\u2019s Disease<\/strong><\/p>\n<p align=\"justify\">In collaboration with JCR Pharmaceuticals (JCR), Acumen Pharmaceuticals investigated methods to help increase the brain penetration of sabirnetug and potentially address critical limitations of traditional antibodies in treating neurological conditions. Using J-Brain Cargo\u00ae, JCR\u2019s clinically validated platform targeting the transferrin receptor (TfR) to facilitate brain uptake, the teams prepared three Bispecific Antibodies of sabirnetug with antibody fragments targeting murine TfR (mTfR), each with varying mTfR affinities. The A\u03b2O affinity and selectivity of each fusion protein were measured via surface plasmon resonance (SPR), while plasma and total brain pharmacokinetics were measured in wild-type mice following a 2 mg\/kg IV injection; brain exposure and target engagement were assessed in ARTE10 AD mice 24 hours after the 2 mg\/kg IV injection with immunohistochemistry. Findings demonstrate that Acumen\u2019s EBD&#x2122; technology utilizing TfR increases sabirnetug brain exposure while preserving target engagement as demonstrated by A\u03b2O selectivity.<\/p>\n<p align=\"justify\"><strong>Sabirnetug Biomarker Treatment Responses: Exploratory Evaluation of the CNS Disease Panel <\/strong><strong>NULISAseq&#x2122;<\/strong><\/p>\n<p align=\"justify\">The Phase 1 INTERCEPT\u2011AD study demonstrated clear, treatment\u2011related biomarker changes following a brief sabirnetug administration. Acumen used the protein-multiplex NULISAseq&#x2122; CNS Disease Panel to measure 127 proteins reflecting amyloid and tau pathology, synaptic function, neuroinflammation and neurodegeneration. Sabirnetug\u2011associated effects were observed in key Alzheimer\u2019s disease biomarkers, including the pTau217\/A\u03b242 ratio, A\u03b21\u201138, and GFAP. The analysis also revealed biologically meaningful correlations across A\u03b2 proteoforms, phosphorylated tau species, and neurofilament markers, further strengthening mechanistic confidence. Importantly, NULISAseq&#x2122; results showed strong concordance with established clinical platforms (Lumipulse\u00ae and ELISA), demonstrating cross\u2011platform robustness and supporting future use of CNS Disease Panels in sabirnetug development. A dedicated bioanalytical database has now been established to enable expanded exploratory analyses, including integration with the ongoing Phase 2 ALTITUDE\u2011AD study. This approach expands our understanding of sabirnetug\u2019s pharmacodynamic signature and efforts towards optimized treatments strategies for Alzheimer\u2019s patients.<\/p>\n<p align=\"justify\"><strong>Development and Characterization of Novel Antibodies Targeting Amyloid Beta Oligomers with High Selectivity<\/strong><\/p>\n<p align=\"justify\">Given the role of soluble A\u03b2Os as early, persistent drivers of AD pathogenesis, Acumen sought to develop and characterize novel, highly selective anti-A\u03b2O antibodies to further enhance selectivity for A\u03b2Os over A\u03b2 monomers, which are \u22657,000-fold more abundant in AD biofluids and tissues. Researchers used SPR to measure antibody affinity and selectivity of these novel anti-A\u03b2O monoclonal antibodies (mAbs) for A\u03b2Os compared to monomers (A\u03b21-28 and A\u03b21-40). The study identified three novel A\u03b2O mAbs of interest, with ACU234 demonstrating notable selectivity \u2013 approximately 21,000-fold greater affinity for oligomeric versus monomeric A\u03b2. ACU234 underwent further evaluation using both <em>in vitro<\/em> and <em>in vivo<\/em> models of target engagement, including staining human brain samples from AD and controls compared to known A\u03b2 mAbs, and injection into ARTE10 transgenic (Tg) mice to assess brain localization. Results confirmed ACU234\u2019s ability to bind disease-relevant A\u03b2Os and endogenous A\u03b2Os in AD brain tissue and Tg mice, respectively, consistent with its characterization as a novel antiA\u03b2O mAb with high selectivity and affinity. Further work is needed to characterize ACU234 and explore its potential as an A\u03b2O-targeting therapeutic.<\/p>\n<p align=\"justify\">The data posters presented will be available after each poster session concludes on the Company&#8217;s website at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XJ9D59It57cqFADtVsOvOHAA-KfQg04XXDeJmOHvug_-3zwFQmLIFwG4cxNNKRzJzLUB7Q9h25KiWVITeZmpKPyscP2Wb17kf_Zbo3bmiYluHgTCZcbC34uqJhDCmvDDIT4Hzq5VpZnJsooHEEkI1A==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/acumenpharm.com\/publications\/<\/a>.<\/p>\n<p align=\"justify\"><strong>About Sabirnetug (ACU193) <\/strong><\/p>\n<p>Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (A\u03b2Os), which are a highly toxic and pathogenic form of A\u03b2, relative to A\u03b2 monomers and amyloid plaques. Soluble A\u03b2Os have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble A\u03b2Os, sabirnetug aims to address the hypothesis that soluble A\u03b2Os are an early and persistent underlying cause of the neurodegenerative process in Alzheimer\u2019s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD.<\/p>\n<p align=\"justify\"><strong>About ALTITUDE-AD (Phase 2)\u00a0 <\/strong><\/p>\n<p>Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer&#8217;s disease. The study has enrolled 542 individuals with early Alzheimer\u2019s disease (mild cognitive impairment or mild dementia due to AD) at multiple investigative sites located in the United States, Canada, the European Union and the United Kingdom. Topline results are expected in late 2026. More information can be found on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WHYLtqwPiWtllGWHkbuvdm3dSyikneOa10Syt4rpLHgyn_Ti_CoXFJqkUUqxSWTFe1Vof1WNcPIXEbQHwJvCnbaIckBaTH_TU_6IZEFiRGg=\" rel=\"nofollow\" target=\"_blank\" title=\"www.clinicaltrials.gov\">www.clinicaltrials.gov<\/a>, NCT identifier NCT06335173.<\/p>\n<p><strong>About Acumen Pharmaceuticals, Inc. <\/strong><\/p>\n<p align=\"justify\">Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease (AD). Acumen\u2019s scientific founders pioneered research on A\u03b2Os, which a growing body of evidence indicates are early and persistent triggers of Alzheimer\u2019s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble A\u03b2Os, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer\u2019s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme\u2019s proprietary ENHANZE\u00ae drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD&#x2122;) therapy for Alzheimer\u2019s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-_OPohdqKB9f9F4OSGcz8Ai3Mvc7DIS45nxXXqWcIkf9K5L_rYpFUG3UI8oA-H0US9LYfaGpzSTKxqHLGO9TYTWo_rgwvIdY6-HEySaa2WCxDYWMtXHY7U7GGDeaRaldB4QjyIgLQnSUYaQOoKX2_cS8d9aALZpdu8Pj1MLdHLY6Q2hWt6BJVWBc8qBRBEMffuqF_C22pboyzDKjanagzsYLhc_qdpIOH-OwKGchlwZt2Tyd5Bi7_cahusancpKs3xO5FvauOGOVV12Ys0g8bQ==\" rel=\"nofollow\" target=\"_blank\" title=\"www.acumenpharm.com\">www.acumenpharm.com<\/a>.<\/p>\n<p align=\"justify\"><strong>About the J-Brain Cargo<\/strong><sup><strong>\u00ae<\/strong><\/sup><strong> Platform Technology<\/strong><\/p>\n<p>JCR Pharmaceuticals has developed a proprietary blood-brain barrier (BBB)-penetrating technology, J-Brain Cargo\u00ae, to bring biotherapeutics into the central nervous system (CNS). The first drug developed based on this technology is IZCARGO<sup>TM<\/sup> (INN: pabinafusp alfa) and is approved in Japan for the treatment of a lysosomal storage disorder.<\/p>\n<p><strong>About JCR Pharmaceuticals Co., Ltd.<\/strong><\/p>\n<p align=\"justify\">JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world\u2019s most complex healthcare challenges. JCR continues to build upon our 50-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. JCR\u2019s innovative therapies address conditions like growth disorder, MPS II, Fabry disease, acute graft-versus-host disease, and renal anemia. JCR is also developing treatments for rare diseases like MPS I, MPS II, MPS IIIA and B, and more. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XJ9D59It57cqFADtVsOvONJn-Wo5h3GlAUk97LJNhPRcemkW2bcJF-4N7Dd_ciuMw-w3ucYEtZ3QTehC1zJtzHlcS-WDUlrsypRZHeIVPH0=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/jcrpharm.com\/<\/a>. <\/p>\n<p><strong>Forward-Looking Statements<\/strong> <\/p>\n<p>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen\u2019s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as \u201cbelieves,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cseeks,\u201d \u201caims,\u201d \u201cplans,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201cmilestone\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen\u2019s business, the therapeutic potential of Acumen\u2019s product candidate, sabirnetug (ACU193) and ACU 234, and the potential to develop a candidate to treat Alzheimer&#8217;s Disease utilizing EBD technology. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen\u2019s programs are described in additional detail in Acumen\u2019s filings with the Securities and Exchange Commission (\u201cSEC\u201d), including in Acumen\u2019s most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.<\/p>\n<p><strong>Investors:<\/strong><br \/>Alex Braun<br \/>abraun@acumenpharm.com<\/p>\n<p><strong>Media:<\/strong><br \/>ICR Healthcare<br \/>AcumenPR@icrhealthcare.com<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmUzMGNkZjMtYjM2OC00MTM2LWJmY2ItYzM0ODgzOWZkZDNkLTEyMjIyMzUtMjAyNi0wMy0xNy1lbg==\/tiny\/Acumen-Pharmaceuticals-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEWTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) &#8212; Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease (AD), today announced new research findings at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders (AD\/PD), taking place [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-78585","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery&#x2122;, Biomarker Research, and Novel Antibodies at Advances in Alzheimer&#039;s Treatment at International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2026 - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery&#x2122;, Biomarker Research, and Novel Antibodies at Advances in Alzheimer&#039;s Treatment at International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2026\" \/>\n<meta property=\"og:description\" content=\"NEWTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) &#8212; Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company develop\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-17T12:05:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml.globenewswire.com\/media\/ZmUzMGNkZjMtYjM2OC00MTM2LWJmY2ItYzM0ODgzOWZkZDNkLTEyMjIyMzUtMjAyNi0wMy0xNy1lbg==\/tiny\/Acumen-Pharmaceuticals-Inc-.png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery&#x2122;, Biomarker Research, and Novel Antibodies at Advances in Alzheimer&#8217;s Treatment at International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2026\",\"datePublished\":\"2026-03-17T12:05:42+00:00\",\"dateModified\":\"2026-03-17T12:05:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/\"},\"wordCount\":1696,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/\",\"name\":\"Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery&#x2122;, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2026 - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-03-17T12:05:42+00:00\",\"dateModified\":\"2026-03-17T12:05:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery&#x2122;, Biomarker Research, and Novel Antibodies at Advances in Alzheimer&#8217;s Treatment at International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery&#x2122;, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2026 - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/","og_locale":"en_US","og_type":"article","og_title":"Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery&#x2122;, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2026","og_description":"NEWTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) &#8212; Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company develop","og_url":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-03-17T12:05:42+00:00","og_image":[{"url":"https:\/\/ml.globenewswire.com\/media\/ZmUzMGNkZjMtYjM2OC00MTM2LWJmY2ItYzM0ODgzOWZkZDNkLTEyMjIyMzUtMjAyNi0wMy0xNy1lbg==\/tiny\/Acumen-Pharmaceuticals-Inc-.png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery&#x2122;, Biomarker Research, and Novel Antibodies at Advances in Alzheimer&#8217;s Treatment at International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2026","datePublished":"2026-03-17T12:05:42+00:00","dateModified":"2026-03-17T12:05:42+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/"},"wordCount":1696,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/","url":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/","name":"Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery&#x2122;, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2026 - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-03-17T12:05:42+00:00","dateModified":"2026-03-17T12:05:42+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-delivery-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery&#x2122;, Biomarker Research, and Novel Antibodies at Advances in Alzheimer&#8217;s Treatment at International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2026"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/78585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=78585"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/78585\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=78585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=78585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=78585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}